A study of 360 cardiac surgery patients found that colchicine reduced postpericardiotomy syndrome, but not postoperative atrial fibrillation or pericardial/pleural effusions. Colchicine also increased the risk of gastrointestinal adverse effects.
A new study has failed to identify a medical treatment for post-operative pericardial effusion (POPE), a potentially serious condition that can lead to cardiac tamponade. The POPE-2 study showed that colchicine had no effect in reducing the volume of fluid around the heart or preventing the risk of cardiac tamponade.
A study of 34 patients with persistent clinical symptoms and neurologic signs of impaired nerve function found that ultrasonography had a concordance rate of 98% with surgical results. The majority of patients (86%) showed good recovery after neurolysis, anastomosis, or transplantation.
The new guidelines provide a risk calculator to estimate five-year risk of sudden cardiac death in HCM patients. The guidelines also recommend genetic testing, specialized tests, and multidisciplinary team referrals to improve diagnosis and management.
The 2014 ESC/EACTS revascularisation guidelines emphasize the therapeutic benefit of revascularisation in coronary artery disease (CAD) for patients with stable CAD. Coronary artery bypass grafting (CABG) reduces the risk of death, myocardial infarction, and repeat revascularisation compared to medical treatment. DES are favored over b...
A new study found that pre-surgical colchicine administration reduced post-pericardiotomy syndrome (PPS) in cardiac surgery patients, but was associated with high gastrointestinal side effects.
The PARADIGM-HF trial found LCZ696 to be superior to enalapril in reducing cardiovascular mortality and hospitalization for heart failure. The study showed a 20% reduction in death from cardiovascular causes and a 21% reduction in hospitalization for heart failure.
The NEART-HF trial found no clinical benefit of vagus nerve stimulation for heart failure patients, despite robust pre-clinical data suggesting a potential therapeutic effect. However, the treatment did show improvements in quality of life and functional classification.
The new document provides clear recommendations on how to identify ACS patients at risk for arrhythmias and manage tachy- and bradyarrhythmias using drugs, devices, and catheter-based approaches. The paper also offers guidance on the use of antiarrhythmic drugs in patients with ACS and ventricular arrhythmias.
The European Society of Cardiology publishes first recommendations on new oral anticoagulants for pulmonary embolism. The guidelines provide detailed recommendations on drug use and risk stratification, including age-adjusted D-dimer cut-offs.
The European Society of Cardiology has published the first expert consensus on ventricular arrhythmias, providing guidelines for diagnosis and management. The recommendations cover a wide range of ventricular arrhythmias, from benign to life-threatening conditions.
The MORE-CRT study demonstrates the safety and efficiency of quadripolar lead technology in managing common pacing complications during cardiac resynchronisation therapy. At six months, patients with quadripolar leads showed a significant reduction in intra- and post-operative LV lead-related complications compared to bipolar lead cont...
A study found that intravenous iron supplementation improved functional capacity and quality of life in heart failure patients with iron deficiency, reducing hospital admissions for worsening heart failure. The treatment also showed benefits in measures of functional status and quality of life.
The new guidelines cover aneurysms, calcifications, congenital diseases, aortic inflammation, and tumors, with improved diagnostic capabilities using imaging technologies. The guidelines recommend opportunistic screening for abdominal aortic aneurysm and the use of hybrid treatments, as well as establishing aortic teams in hospitals.
The European Lead Extraction ConTRolled (ELECTRa) registry found that transvenous lead extraction is clinically successful in over 98% of cases, with a failure rate of 1.5%. Non-infective indications for lead extraction are becoming increasingly common, accounting for 47.3% of cases.